Innovatus Imaging Expands RapidRepair Program

Innovatus Imaging has announced the expansion of its RapidRepair program which began April 2019 and provided 5-day worst-case repair times for the Philips X7 and X8-2t TEE probes.  “We’ve invested millions in improving infrastructure and staff, accelerating our training programs, increasing efficiencies, and developing additional proprietary processes,” says Matt Tomory. “Our RapidRepair processes enable devices to be evaluated, repaired, tested, and returned in the most efficient manner possible and are key to our customers maintaining workflow, high-quality patient care, and the financial bottom line.”

RapidRepair for MRI coils will be executed at Innovatus Imaging’s MRI Center of Excellence in Pittsburgh and ultrasound probes at the company’s Ultrasound Center of Excellence in Tulsa, Oklahoma. RapidRepair allows us to get the most popular makes and models of ultrasound probes and MRI coils back to technologists faster than ever before while remaining consistent with OEM design.”  For more information on RapidRepair, and the full line of products supported by Innovatus Imaging.

Moving forward, customers can expect increased efficiency while maintaining the same high level of quality that they expect from Innovatus Imaging. Currently, Innovatus Imaging is the only repair provider offering a 12-month warranty on ALL standard probes.  Specialty probes and MRI coils are backed by a 6-month warranty.

Innovatus Imaging is the ISO-13485:2016 certified preferred provider for best-in-class repair services for medical imaging products. The company’s expertise spans the entire device lifecycle – from design, development, manufacturing to sales, distribution, and repair. With a legacy spanning over 30 years and having repaired more than 160,000 ultrasound probes and 30,000+ MRI coils, the company has accumulated tremendous amounts of data which serves as a massive knowledge base for continual improvement. The company has an FDA-registered site for the design and manufacturing of ultrasound transducers and related products. Headquartered in Pittsburgh, Innovatus Imaging also maintains Centers of Excellence in Tulsa, OK and Denver, CO.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”